CoChat

Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis

Open access
Grasselli, G, Rossi, S, Musella, A, Gentile, A, Loizzo, S, Muzio, L, Di Sanza, C, Errico, F, Musumeci, G, Haji, N, Fresegna, D, Sepman, H, De Chiara, V, Furlan, R, Martino, G, Usiello, A, Mandolesi, G, Centonze, D · 2013 · British Journal of Pharmacology
Cited by 47

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Glutamate transmission is dysregulated in both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), the animal model of MS. A characteristic of EAE is increased glutamate transmission associated with up‐regulation of AMPA receptors. However, little is known about the role of NMDA receptors in the synaptic modifications induced by EAE. Experimental Approach: The contribution of NMDA receptors to the alterations of glutamate transmission and disease severity in EAE mice was assessed by means of neurophysiological, morphological, Western blot, metabolic and clinical score assessments. Key Results: I n our EAE mice, there was an NMDA receptor‐dependent increase of glutamate release, associated with marked activation of the astroglia. Presynaptic NMDA receptors became overactive during EAE, increasing synaptic glutamate release by a mechanism dependent on voltage‐gated sodium channels. By means of NAD(P)H autofluorescence analysis, we also found that EAE has a glutamate and NMDA receptor‐dependent dysfunction of mitochondrial activity, which is known to contribute to the neurodegenerative damage of MS and EAE. Furthermore, pharmacological blockade of NMDA receptors in vivo ameliorated both synaptic transmission defects and of the clinical disease course of EAE mice, while EAE induced in mice with a genetically enhanced NMDA receptor signalling had opposite effects. Conclusions and Implications: Our data, showing both sensitization of NMDA receptors and their involvement in the progression of the EAE disease, supggest that pharmacological impairment of NMDA receptor signalling would be a component of a neuroprotection strategy in MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2012.02178.x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 47

Metadata

Authors
Grasselli, G., Rossi, S., Musella, A., Gentile, A., Loizzo, S., Muzio, L., Di Sanza, C., Errico, F., Musumeci, G., Haji, N., Fresegna, D., Sepman, H., De Chiara, V, Furlan, R., Martino, G., Usiello, A., Mandolesi, G., & Centonze, D.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-12-20
Volume
168
Issue
2
Pages
502-517
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1587172615
Cited by
47
References
11
FWCI
1.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.02178.x
The paper
Grasselli, G., Rossi, S., Musella, A., Gentile, A., Loizzo, S., Muzio, L., Di Sanza, C., Errico, F., Musumeci, G., Haji, N., Fresegna, D., Sepman, H., De Chiara, V, Furlan, R., Martino, G., Usiello, A., Mandolesi, G., & Centonze, D. (2013). Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.02178.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.